Perspective for Prophylaxis and Treatment of Cervical Cancer: An Immunological Approach

As the second most common cause of cancer-related death in women, human papilloma virus (HPV) vaccines have been a major step in decreasing the morbidity and mortality associated with cervical cancer. An estimated 490,000 women are diagnosed with cervical cancer each year. Increasing knowledge of th...

Full description

Saved in:
Bibliographic Details
Published in:International Reviews of Immunology 2012-02, Vol.31 (1), p.3-21
Main Authors: Jenkins, Marjorie, Chiriva-Internati, Maurizio, Mirandola, Leonardo, Tonroy, Catherine, Tedjarati, Sean S., Davis, Nicole, D'Cunha, Nicholas, Tijani, Lukman, Hardwick, Fred, Nguyen, Diane, Kast, W. Martin, Cobos, Everardo
Format: Article
Language:English
Subjects:
Alphapapillomavirus - immunology
Animals
cancer vaccines
Carcinoma - prevention & control
Carcinoma - therapy
Cell Transformation, Neoplastic
Cell Transformation, Viral
Female
gynecologic oncology
HPV
Humans
immunotherapy
Immunotherapy, Active
Papillomavirus Infections - prevention & control
Papillomavirus Vaccines - therapeutic use
Sexually Transmitted Diseases, Viral - complications
Sexually Transmitted Diseases, Viral - prevention & control
Sexually Transmitted Diseases, Viral - virology
tumor prevention
Uterine Cervical Neoplasms - prevention & control
Uterine Cervical Neoplasms - therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:As the second most common cause of cancer-related death in women, human papilloma virus (HPV) vaccines have been a major step in decreasing the morbidity and mortality associated with cervical cancer. An estimated 490,000 women are diagnosed with cervical cancer each year. Increasing knowledge of the HPV role in the etiology of cervical cancer has led to the development and introduction of HPV-based vaccines for active immunotherapy of cervical cancer. Immunotherapies directed at preventing HPV-persistent infections. These vaccines are already accessible for prophylaxis and in the near future, they will be available for the treatment of preexisting HPV-related neoplastic lesions.
ISSN:0883-0185
1937-4364
1563-5244
DOI:10.3109/08830185.2011.637254